Landec Corporation Free Cash Flow

Free Cash Flow of LNDC for past 10 years: annual, quarterly and twelve month trailing (TTM) including Free Cash Flow growth rates and interactive chart. Free cash flowis calculated as operating cash flow minus of capital expenditures. Interest payments are excluded from the generally accepted definition of free cash flow. Free cash flow is the cash flow available to all the investors in a company, including common stockholders, preferred shareholders, and lenders. Some investors prefer FCF or FCF per share over earnings and earnings per share as a measure of profitability. However, because FCF accounts for investments in property, plant, and equipment it can be lumpy over time. Free cash flow is usually used in discounted cash flow models to determine a company's intrinsic value.

Highlights and Quick Summary

  • Free Cash Flow for the quarter ending February 27, 2021 was $-20.2 Million (a -439.32% decrease compared to previous quarter)
  • Year-over-year quarterly Free Cash Flow increased by 17.03%
  • Annual Free Cash Flow for 2020 was $-41.3 Million (a 45.14% increase from previous year)
  • Annual Free Cash Flow for 2019 was $-28.5 Million (a 107.5% increase from previous year)
  • Annual Free Cash Flow for 2018 was $-13.7 Million (a -298.25% decrease from previous year)
  • Twelve month Free Cash Flow ending February 27, 2021 was $-14.8 Million (a -219.93% decrease compared to previous quarter)
  • Twelve month trailing Free Cash Flow decreased by -64.2% year-over-year
Trailing Free Cash Flow for the last four month:
27 Feb '21 29 Nov '20 30 Aug '20 30 May '20
$-14.8 Million $12.3 Million $-9.15 Million $-41.3 Million
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Free Cash Flow of Landec Corporation

Most recent Free Cash Flowof LNDC including historical data for past 10 years.

Interactive Chart of Free Cash Flow of Landec Corporation

Landec Corporation Free Cash Flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-20.21
2020 $5.96 $16.74 $-17.27 $6.9 $-41.29
2019 $-15.52 $-15.4 $-12.99 $-1.67 $-28.45
2018 $-1.53 $-12.25 $-13.36 $2.68 $-13.71
2017 $-0.79 $-2.23 $-6.85 $12.96 $6.92
2016 $-3.54 $4.35 $0.8 $-6.77 $-17.41
2015 $-7.67 $-5.16 $6.08 $7.88 $10.18
2014 $-3.63 $-0.16 $2.52 $7.03 $6.16
2013 $-3.58 $0.19 $3.42 $9.83 $12.35
2012 $-3.95 $3.06 $12.17 $8.43 $16.81
2011 $-6.58 $2.8 $0.23 $8.94 $7.79
2010 $-4.09 $2.71 $-1.04 $2.29

Business Profile of Landec Corporation

Sector: Consumer Defensive
Industry: Packaged Foods
Landec Corporation, together with its subsidiaries, designs, develops, manufactures, and sells differentiated health and wellness products for food and biomaterials markets. It operates through Curation Foods and Lifecore segments. The Curation Foods segment engages in processing, marketing, and selling of vegetable-based salads, and fresh-cut and whole vegetable products primarily under the Eat Smart brand, O branded olive oils and wine vinegars, and Yucatan and Cabo Fresh guacamole and avocado food products, as well as various private labels. It serves retail grocery chains, club stores, and food service operators. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology transfer, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. It sells its products directly to partners in the medical device and pharmaceutical markets. The company was founded in 1986 and is headquartered in Santa Clara, California.